Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9912781 | 0.93 | BRAF (0.80) | BRAF | |
| SCHEMBL14964610 | 0.92 | BRAF (0.79) | BRAF | |
| SCHEMBL9912744 | 0.92 | BRAF (0.80) | BRAF | |
| SCHEMBL14964670 | 0.91 | BRAF (0.70) | BRAF | |
| SCHEMBL9912801 | 0.91 | BRAF (0.78) | BRAF | |
| SCHEMBL9912803 | 0.91 | BRAF (0.80) | BRAF | |
| SCHEMBL16139170 | 0.91 | BRAF (0.69) | BRAF | |
| SCHEMBL9912750 | 0.90 | BRAF (0.81) | BRAF | |
| SCHEMBL9912743 | 0.89 | BRAF (0.80) | BRAF | |
| SCHEMBL9912764 | 0.89 | BRAF (0.79) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780341-B1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-02-13 | — | — | EP | disclosed |
| EP-2780341-B1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-02-13 | — | — | EP | disclosed |
| US-9550781-B2 | Kinase modulating compounds, compositions containing the same and use thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-9550781-B2 | Kinase modulating compounds, compositions containing the same and use thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-9550781-B2 | Kinase modulating compounds, compositions containing the same and use thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2017-01-24 | — | — | US | disclosed |
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-10-02 | — | — | US | disclosed |
| EP-2780341-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | Centaurus Biopharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013071865-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013071865-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296261-A1 | KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF | MAP3K20, MAP3K1, PRKCH | BRAF 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.